NexTel Medical Forms JV to Launch Exosome Hair Regrowth Product in Q4
MAJI has more than doubled off its 52-week low of $0.002 on light trading volume (0.2× avg).
Summary
NexTel Medical signed a definitive joint venture to commercialize a patented hair regeneration formula using its exosome delivery system. The product targets a global hair restoration market projected to reach $18.7B-$23.1B by 2030-2032, with U.S. market currently at $2.3B. Commercial launch is targeted for Q4 2026, and the partners plan to file a joint patent on the enhanced platform. This follows the company's recent Regulation A offering priced at $0.003 per share, which raised capital for operations. The JV adds a near-term commercial catalyst to a clinical-stage biotech with a micro-cap valuation.
At the time of this announcement, MAJI was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $440.2K. The 52-week trading range was $0.00 to $0.21. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.